Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Namm DH and High JA | Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. | 1980 | Thromb. Res. | pmid:7209881 |
Tencé V et al. | Release, purification, and characterization of platelet-activating factor (PAF). | 1980 | Biochimie | pmid:17941181 |
Godfroid JJ et al. | Platelet activating factor (PAF-acether): total synthesis of 1-O-octadecyl 2-O-acetyl sn-glycero-3-phosphoryl choline. | 1980 | FEBS Lett. | pmid:7409144 |
Clark PO et al. | Physical and chemical properties of platelet-activating factor obtained from human neutrophils and monocytes and rabbit neutrophils and basophils. | 1980 | Biochim. Biophys. Acta | pmid:7357030 |
[Do you know PAF?]. | 1980 | Nouv Presse Med | pmid:7367260 | |
Farr RS et al. | Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). | 1980 | Clin. Immunol. Immunopathol. | pmid:7371225 |
McManus LM et al. | Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. | 1980 | J. Immunol. | pmid:7373056 |
Cusack NJ | Platelet-activating factor. | 1980 | Nature | pmid:7374771 |
Check WA | A new age in asthma research: study of chemical mediators. | 1980 Aug 22-29 | JAMA | pmid:6104737 |
Suzuki K et al. | The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. | 1980 Feb 1-15 | Thromb. Res. | pmid:6966083 |
Chignard M et al. | [Platelet aggregation and platelet activating factor (author's transl)]. | 1980 Oct-Dec | J Pharmacol | pmid:7206730 |
Camussi G et al. | Platelet-activating factor (PAF), a mediator of platelet aggregation. Effect of corticosteroids on PAF-induced platelet aggregation. | 1980 Oct-Dec | Minerva Nefrol | pmid:7254682 |
Hanahan DJ et al. | Potent platelet stimulating activity of enantiomers of acetyl glyceryl ether phosphorylcholine and its methoxy analogues. | 1981 | Biochem. Biophys. Res. Commun. | pmid:7236259 |
Cox CP et al. | The presence of platelet-activating factor (PAF) in normal human mixed saliva. | 1981 | J. Immunol. | pmid:7240750 |
O'Donnell MC et al. | Platelet activating factor: an inhibitor of neutrophil activation? | 1981 | Clin. Exp. Immunol. | pmid:7249391 |
Furlan M et al. | Binding of colloidal gold granules, coated with bovine factor VIII, to human platelet membranes. | 1981 | Br. J. Haematol. | pmid:6786321 |
Stimler NP et al. | Anaphylactic actions of platelet-activating factor. | 1981 | Am. J. Pathol. | pmid:6975043 |
Benveniste J et al. | Platelet-activating factor (PAF-acether): molecular aspects of its release and pharmacological actions. | 1981 | Int. Arch. Allergy Appl. Immunol. | pmid:7030966 |
Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |